WAYNE, PA — A groundbreaking study published in the Nature journal Prostate Cancer and Prostatic Diseases has bolstered the position of the UroLift™ System as the leading minimally invasive surgical treatment (MIST) for benign prostatic hyperplasia (BPH), or enlarged prostate. The system is developed by Teleflex Incorporated (NYSE: TFX), a global provider of medical technologies.
The peer-reviewed research, titled “Retreatment Rates and Postprocedural Complications Are Higher Than Expected After BPH Surgeries: A U.S. Healthcare Claims and Utilization Study,” is the most extensive longitudinal healthcare claims study evaluating complication and retreatment rates after BPH treatment with leading surgical and MIST procedures.
The study provides critical insights for patients and providers assessing BPH therapies. It directly compares and analyzes outcomes in over 40,000 real-world BPH patients, applying a consistent definition of retreatment across the leading BPH treatments. The results reveal that within one year of BPH surgery, approximately one in twenty patients may require retreatment, regardless of the treatment method used.
Steven Kaplan, MD, professor of Urology at the Icahn School of Medicine and lead author of the paper, commented, “With this large-scale analysis, we aimed to provide a way for urologists and patients to understand retreatment for BPH therapies in a real-world setting.” He further emphasized the elevated rate of surgical retreatment occurring after TURP and GreenLight™ PVP within the first year.
In addition to retreatment rates, the study also assessed the complications following BPH surgery, defined as a “return procedure” in an outpatient setting. Under this definition, at one-year procedural complications were lowest following the UroLift™ System and highest following Rezūm™ WVTT.
Teleflex Incorporated, the company behind the UroLift™ System, is renowned for its commitment to improving the health and quality of people’s lives. Liam Kelly, Chairman, President, and CEO of Teleflex, is scheduled to speak at the 35th Annual Piper Sandler Healthcare Conference in New York City, on November 28.
The research findings will be further discussed by Dr. Kaplan in a 60-minute live webinar hosted by Teleflex on November 30, 2023. The study was financially supported by Teleflex Incorporated.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.